393 related articles for article (PubMed ID: 25315076)
21. Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis.
Verstovsek S
Postgrad Med; 2013 Jan; 125(1):128-35. PubMed ID: 23391678
[TBL] [Abstract][Full Text] [Related]
22. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.
Verstovsek S; Kantarjian HM; Estrov Z; Cortes JE; Thomas DA; Kadia T; Pierce S; Jabbour E; Borthakur G; Rumi E; Pungolino E; Morra E; Caramazza D; Cazzola M; Passamonti F
Blood; 2012 Aug; 120(6):1202-9. PubMed ID: 22718840
[TBL] [Abstract][Full Text] [Related]
23. Ruxolitinib: in the treatment of myelofibrosis.
Yang LP; Keating GM
Drugs; 2012 Nov; 72(16):2117-27. PubMed ID: 23061804
[TBL] [Abstract][Full Text] [Related]
24. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.
Harrison CN; Vannucchi AM; Platzbecker U; Cervantes F; Gupta V; Lavie D; Passamonti F; Winton EF; Dong H; Kawashima J; Maltzman JD; Kiladjian JJ; Verstovsek S
Lancet Haematol; 2018 Feb; 5(2):e73-e81. PubMed ID: 29275119
[TBL] [Abstract][Full Text] [Related]
25. Practical management of patients with myelofibrosis receiving ruxolitinib.
Harrison C; Mesa R; Ross D; Mead A; Keohane C; Gotlib J; Verstovsek S
Expert Rev Hematol; 2013 Oct; 6(5):511-23. PubMed ID: 24083419
[TBL] [Abstract][Full Text] [Related]
26. Ruxolitinib: a review of its use in patients with myelofibrosis.
Plosker GL
Drugs; 2015 Feb; 75(3):297-308. PubMed ID: 25601187
[TBL] [Abstract][Full Text] [Related]
27. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis.
Vannucchi AM; Kantarjian HM; Kiladjian JJ; Gotlib J; Cervantes F; Mesa RA; Sarlis NJ; Peng W; Sandor V; Gopalakrishna P; Hmissi A; Stalbovskaya V; Gupta V; Harrison C; Verstovsek S;
Haematologica; 2015 Sep; 100(9):1139-45. PubMed ID: 26069290
[TBL] [Abstract][Full Text] [Related]
28. Practical management of myelofibrosis with ruxolitinib.
Ho PJ; Marlton P; Tam C; Stevenson W; Ritchie D; Bird R; Dunlop LC; Durrant S; Ross DM
Intern Med J; 2015 Dec; 45(12):1221-30. PubMed ID: 26648193
[TBL] [Abstract][Full Text] [Related]
29. Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012.
Reilly JT; McMullin MF; Beer PA; Butt N; Conneally E; Duncombe AS; Green AR; Mikhaeel G; Gilleece MH; Knapper S; Mead AJ; Mesa RA; Sekhar M; Harrison CN
Br J Haematol; 2014 Nov; 167(3):418-20. PubMed ID: 24961987
[No Abstract] [Full Text] [Related]
30. Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.
Arana Yi C; Tam CS; Verstovsek S
Future Oncol; 2015; 11(5):719-33. PubMed ID: 25757677
[TBL] [Abstract][Full Text] [Related]
31. Ruxolitinib for myelofibrosis--an update of its clinical effects.
Kantarjian HM; Silver RT; Komrokji RS; Mesa RA; Tacke R; Harrison CN
Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):638-45. PubMed ID: 24238036
[TBL] [Abstract][Full Text] [Related]
32. Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I.
Miller CB; Komrokji RS; Mesa RA; Sun W; Montgomery M; Verstovsek S
Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):479-487. PubMed ID: 28606598
[TBL] [Abstract][Full Text] [Related]
33. Ruxolitinib for myelofibrosis.
Haznedaroglu IC
N Engl J Med; 2012 May; 366(21):2032; author reply 2032-5. PubMed ID: 22621635
[No Abstract] [Full Text] [Related]
34. Ruxolitinib for myelofibrosis.
Koschmieder S; Koppelle A; Seifert H
N Engl J Med; 2012 May; 366(21):2031-2; author reply 2032-4. PubMed ID: 22621634
[No Abstract] [Full Text] [Related]
35. Ruxolitinib for myelofibrosis.
Diamantidis MD
N Engl J Med; 2012 May; 366(21):2031; author reply 2032-4. PubMed ID: 22621633
[No Abstract] [Full Text] [Related]
36. Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy.
Pemmaraju N; Bose P; Rampal R; Gerds AT; Fleischman A; Verstovsek S
Leuk Lymphoma; 2023 Jun; 64(6):1063-1081. PubMed ID: 37081809
[TBL] [Abstract][Full Text] [Related]
37. JAK2 inhibitors for myeloproliferative neoplasms: what is next?
Bose P; Verstovsek S
Blood; 2017 Jul; 130(2):115-125. PubMed ID: 28500170
[TBL] [Abstract][Full Text] [Related]
38. Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I.
Mesa RA; Verstovsek S; Gupta V; Mascarenhas JO; Atallah E; Burn T; Sun W; Sandor V; Gotlib J
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):214-221.e1. PubMed ID: 25682576
[TBL] [Abstract][Full Text] [Related]
39. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I.
Verstovsek S; Mesa RA; Gotlib J; Levy RS; Gupta V; DiPersio JF; Catalano JV; Deininger MW; Miller CB; Silver RT; Talpaz M; Winton EF; Harvey JH; Arcasoy MO; Hexner EO; Lyons RM; Raza A; Vaddi K; Sun W; Peng W; Sandor V; Kantarjian H;
Haematologica; 2015 Apr; 100(4):479-88. PubMed ID: 25616577
[TBL] [Abstract][Full Text] [Related]
40. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.
Verstovsek S; Kantarjian H; Mesa RA; Pardanani AD; Cortes-Franco J; Thomas DA; Estrov Z; Fridman JS; Bradley EC; Erickson-Viitanen S; Vaddi K; Levy R; Tefferi A
N Engl J Med; 2010 Sep; 363(12):1117-27. PubMed ID: 20843246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]